In-house roundup: Poll shows UPC attractive without UK; generics support European SPC system; antibody case law better in US than Europe

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

In-house roundup: Poll shows UPC attractive without UK; generics support European SPC system; antibody case law better in US than Europe

Money

Managing IP rounds up the latest news and analysis from patent-focused businesses



Money

Survey: UPC still attractive without UK

In a Patent Strategy poll of more than 50 in-house counsel, 78% of respondents said a harmonised European patent system would still be useful if a post-Brexit UK were unable to participate. Read more... 


Poll: SPC system wanted by most generics

In part two of Patent Strategy’s survey, almost all in-house respondents backed a European SPC system, but were less unified on the SPC Regulation’s reliability for new technologies or third-party MAs. Read more... 


Antibody case law clearer in the US than Europe

Pharma innovators say clearer standards on how monoclonal antibody patent applications are reviewed at the USPTO and US national courts have made it easier to file patents there than at the EPO. Read more... 




more from across site and SHARED ros bottom lb

More from across our site

Julia Bishop is director of IP at Twilio in the US
Hellberg is an IP director at Essity in Sweden
Palińska is the business & IP law lead at CD Projekt Red in Poland
Teemu Itälä is head of legal and compliance for technology standards at Nokia in Finland
David Degen is senior IP counsel at Novartis, Switzerland
Demetrio Roberto Cavicchia is an IP director at Angelini Pharma in Italy
Schwitulla is the head of litigation management at Nokia in Germany
Almeida is the IP group leader at Bosch in Brazil
Amanda Luz is brand protection manager - global at Adidas in the US
Samantak Ghosh is vice president of IP at Avere Therapeutics in the US
Gift this article